Close
Achema middle east
swop processing & packaging

FDA approves TYSABRI label change

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Optimizing Pharma Packaging for Shipping & Distribution Resilience

Building Robust Supply Chain Networks Through Strategic Packaging Design The...

Pharma Packaging Traceability: Drug to Patient Compliance Tool

Traceability from Drug to Patient: Packaging as a Compliance...

End-of-Line Pharma Packaging Trends in Automated Palletizing

End-of-Line Pharma Packaging: Trends in Automated Palletizing & Depalletizing Transforming...

Biogen Idec and Elan have announced the FDA approval of a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS).

The new label identifies anti-JCV antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal leukoencephalopathy (PML).

The new label states that anti-JCV antibody negative status indicates that exposure to the JC virus has not been detected.

Patients who are anti-JCV antibody positive have a higher risk of developing PML.

Patients who are anti-JCV antibody positive, have received prior immunosuppressant (IS) therapy and received treatment with TYSABRI for more than two years have the highest risk of developing PML.

Biogen CEO George Scangos said TYSABRI has benefited thousands of patients worldwide who are living with multiple sclerosis, an often devastating disease affecting people in the prime of their lives.

“Biogen Idec and Elan’s use of novel research and scientific expertise has allowed us to gain a better understanding of the benefit-risk profile for TYSABRI,” Scangos added.

Latest stories

Related stories

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Optimizing Pharma Packaging for Shipping & Distribution Resilience

Building Robust Supply Chain Networks Through Strategic Packaging Design The...

Pharma Packaging Traceability: Drug to Patient Compliance Tool

Traceability from Drug to Patient: Packaging as a Compliance...

End-of-Line Pharma Packaging Trends in Automated Palletizing

End-of-Line Pharma Packaging: Trends in Automated Palletizing & Depalletizing Transforming...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »